Ophthalmology Journal

Dr. Emily Schehlein discusses recent guidelines from the American Glaucoma Society and the American Academy of Ophthalmology on Nicotinamide use for glaucoma neuroprotection with lead author, Dr. Aakriti Garg Shukla. Published in Ophthalmology Glaucoma, "American Glaucoma Society-American Academy of Ophthalmology Position Statement on Nicotinamide Use for Glaucoma Neuroprotection" American Glaucoma Society-American Academy of Ophthalmology Position Statement on Nicotinamide Use for Glaucoma Neuroprotection. Shukla, Aakriti Garg; Cioffi, George A.; John, Simon W.M; Wang, Qing; Liebmann, Jeffrey M. et al. Ophthalmology Glaucoma, Volume 8, Issue 2, 112 – 116. Sign up for the next Ophthalmology Journal Virtual Club on August 27, 2025, at https://store.aao.org/ophthalmology-virtual-journal-club.html

Single-use disposable plastics and other materials have increased in use since the start of the COVID-19 pandemic. This generates increased waste and cost in eye care. Dr. Emily Schehlein and Dr. Alan Robin discuss their recent Ophthalmology Glaucoma editorial, "Should We Use Disposable Tonometers and Gonioprisms in the Office?" with recommendations on how and why eye care professionals should clean and reuse tonometry tips and gonioscopy lenses to reduce ophthalmic waste. Should We Use Disposable Tonometers and Gonioprisms in the Office? Schehlein, Emily M., Robin, Alan L. et al. Ophthalmology Glaucoma, Volume 8, Issue 2, 109 – 111.

Marie-Michele Macaron, a fourth-year medical student at St. George's University of London and the first author of a pivotal manuscript on diabetic retinopathy, joins esteemed experts to discuss groundbreaking insights. They compare anti-VEGF injections with panretinal photocoagulation laser therapy, revealing significant findings on treatment safety and effectiveness. The conversation highlights the nuances of patient preferences and the importance of comprehensive studies to optimize care in managing diabetic retinopathy, particularly regarding visual acuity and complications.

Dr. Tsui reveals crucial insights on the risk of uveitis for patients starting glaucoma medications, especially prostaglandin analogs. Collaborative research sheds light on treatment options and their associated risks. The discussion evaluates the safety of these medications, revealing they don't necessarily increase inflammation compared to alternatives. Additionally, the episode explores personalized treatment strategies for patients with complex ophthalmic conditions, emphasizing the need for tailored clinical judgment.

How accurate are diagnoses from ChatGPT? Can ophthalmologists distinguish between artificial intelligence and human responses? Dr. Tsui speaks with Drs. Jimmy S. Chen and David B. Granet on their Ophthalmology Science article, "Analysis of ChatGPT Responses to Ophthalmic Cases: Can ChatGPT Think like an Ophthalmologist?" Analysis of ChatGPT Responses to Ophthalmic Cases: Can ChatGPT Think like an Ophthalmologist? Chen, Jimmy S. et al. Ophthalmology Science, Volume 5, Issue 1. Sign up for the next Ophthalmology Journal Virtual Club on April 23, 2025, at https://store.aao.org/ophthalmology-virtual-journal-club.html

Dr. Drew Carey speaks with Dr. Tongalp H. Tezel on his study comparing patients with nonarteritic ischemic optic neuropathy (NAION) with healthy non-NAION patients with crowded discs and noncrowded optic discs. From his Ophthalmology article, "Vitreopapillary Findings in Nonarteritic Ischemic Optic Neuropathy versus Healthy Eyes." Vitreopapillary Findings in Nonarteritic Ischemic Optic Neuropathy versus Healthy Eyes. Hondur, Ahmet M. et al. Ophthalmology, Volume 132, Issue 3, 327 – 334 CALL FOR ABSTRACTS! Now accepting paper, poster, and video submissions through April 8. Imagine presenting at AAO 2025; learn more and submit yours at aao.org/pod25

Dr. Edmund Tsui is joined by Dr. Majda Hadziahmetovic to discuss her meta-analysis and systematic review investigating the effectiveness of systemic and local treatments in slowing autoimmune retinopathy progression. From the Ophthalmology Science article, "Clinical Outcomes of Therapeutic Interventions for Autoimmune Retinopathy: A Meta-analysis and Systematic Review." Clinical Outcomes of Therapeutic Interventions for Autoimmune Retinopathy: A Meta-analysis and Systematic Review. Kapoor, Ishani et al. Ophthalmology Science, Volume 5, Issue 1. CALL FOR ABSTRACTS! Now accepting paper, poster, and video submissions through April 8. Imagine presenting at AAO 2025; learn more and submit yours at aao.org/pod25

Ophthalmology Editor-in-Chief, Russell Van Gelder, MD, PhD, and our new Associate Editor, Laura Downie, BOptom, PhD, guest host this special episode introducing "Ophthalmology Reviews." Ophthalmology Reviews is a new section in our flagship journal for structured systematic reviews and meta-analyses. The two editors discuss the importance of these reviews in our field and what our journal is looking for from authors in these types of submissions. For more information, read their recent editorial in Ophthalmology, "Gargantua, The Scholarship of Synthesis and the Evolution of the Ophthalmology Family Journals" and review our Guide for Authors section on Systematic Reviews and Meta-analysis. If you have any questions about submissions, please contact the editorial staff at aaojournal@aao.org. Gargantua, The Scholarship of Synthesis and the Evolution of the Ophthalmology Family Journals. Van Gelder, Russell N. Downie, Laura E. Ophthalmology, Volume 132, Issue 1, 12 – 13.

A revelation while scuba diving leads to a novel device designed to reduce IOP pressure. Dr. Emily Schehlein speaks with Drs. Katherine S. Peters and Daniel Terveen about their study on the FSYX Ocular Pressure Adjusting Pump, from their recent Ophthalmology Glaucoma article, "Manometric Intraocular Pressure Reduction with Negative Pressure Using Ocular Pressure Adjusting Pump Goggles" Manometric Intraocular Pressure Reduction with Negative Pressure Using Ocular Pressure Adjusting Pump Goggles. Peters, Katherine S. et al. Ophthalmology Glaucoma, Volume 8, Issue 1, 22 – 27.

How do GLP-1 receptor agonists and metformin affect glaucoma risk in patients with Type 2 diabetes? Join Dr. Ike Ahmed and Jawad Muayad as they discuss the data on diabetes treatments and glaucoma risk with Dr. Emily Schehlein. From their Ophthalmology article, "Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes." Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes. Muayad, Jawad et al. Ophthalmology. In press.